Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective 20,000-person Nasopharyngeal Carcinoma (NPC) Screening Programme Using Plasma Epstein-Barr Virus (EBV) DNA Analysis

NCT02063399 is registered in ClinicalTrials.gov with Chinese University of Hong Kong as lead sponsor.

NCT NCT02063399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02063399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective 20,000-person Nasopharyngeal Carcinoma (NPC) Screening Programme Using Plasma Epstein-Barr Virus (EBV) DNA Analysis
Lead sponsor
Chinese University of Hong Kong
Phase
Observational
Overall status
Unknown status
Start date
July 31, 2013
Completion date
June 30, 2023
Enrollment
20,302 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal carcinoma